BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28494469)

  • 1. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival.
    Amit M; Tam S; Abdelmeguid AS; Roberts DB; Takahashi Y; Raza SM; Su SY; Kupferman ME; DeMonte F; Hanna EY
    Br J Cancer; 2017 Jun; 116(12):1564-1571. PubMed ID: 28494469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
    Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
    Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
    Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
    Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas: An Analysis With Newly Found Molecular Alterations and Some Population-Based Molecular Differences.
    Wroblewska JP; Mull J; Wu CL; Fujimoto M; Ogawa T; Marszalek A; Hoang MP
    Am J Surg Pathol; 2019 Feb; 43(2):168-177. PubMed ID: 30273197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.
    Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
    Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
    Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
    Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
    Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
    Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
    Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD
    Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational profiling of acral melanomas in Korean populations.
    Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
    Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.